Skip to main content
. Author manuscript; available in PMC: 2025 Jan 5.
Published in final edited form as: HIV Med. 2015 Apr;16(Suppl 1):129–136. doi: 10.1111/hiv.12241

Table 2: Baseline characteristics associated with liver fibrosis in Liver Fibrosis Substudy participants.

BMI (kg/m 2 ; median, IQR) 22.9 [20.9, 25.2]
Smoking Status (N,%)
 Current 85 (37.0)
 Former 27 (11.7)
 Never 118 (51.3)
Alcohol Consumption - Days Per Week (N,%)
 0 77 (34.7)
 < 1 78 (35.6)
 1 – 3 44 (19.2)
 4 – 7 23 (10.5)
Alcohol Consumption - Drinks at a Time (N,%)
 0 51 (22.8)
 1 41 (18.3)
 2 – 4 93 (42.0)
 5 – 7 24 (11.0)
 >8 13 (5.9)
Medical History (N,%)
 Cirrhosis 0 (0.0)
 Chronic liver disease (excluding infectious hepatitis) 1 (0.4)
 Hepatic steatosis 0 (0.0)
 Diabetes mellitus 5 (2.2)
 Alcoholism or substance dependence 2 (0.9)
Concomitant Treatments at Baseline (N,%)
 Fibric acid 1 (0.4)
 Statins 2 (0.9)
 Anti-tuberculous drugs 0 (0.0)
 Drug treatment for hepatitis C 0 (0.0)
 Anabolic steroids 0 (0.0)
 Systemic corticosteroids 1 (0.4)
 Systemic antifungal drugs 1 (0.4)